If so, the use of clinically approved L-type calcium channel blockers to target CaV1.1e currents might be a viable strategy to alleviate the symptoms of DM1 (Benedetti et al., 2015). The gene discussed is CACNA1S; the disease is myotonic dystrophy type 1.